Literature DB >> 34153016

Antiretroviral Drug Transporters and Metabolic Enzymes in Circulating Monocytes and Monocyte-Derived Macrophages of ART-Treated People Living With HIV and HIV-Uninfected Individuals.

Tozammel M D Hoque1, Amélie Cattin2,3, Sana-Kay Whyte-Allman1, Lee Winchester4, Courtney V Fletcher4, Jean-Pierre Routy5, Petronela Ancuta2,3, Reina Bendayan1.   

Abstract

ABSTRACT: Membrane-associated drug transport proteins and drug metabolic enzymes could regulate intracellular antiretroviral (ARV) drug concentrations in HIV-1 target cells such as myeloid cells. We investigated the expression of these transporters and enzymes in monocyte subsets and monocyte-derived macrophages (MDMs) isolated from peripheral blood mononuclear cells (PBMCs) of HIV-uninfected individuals (HIV-negative) and people living with HIV receiving viral suppressive antiretroviral therapy (ART; HIV+ART) and examined plasma and intracellular ARV concentrations. Monocytes were isolated from PBMCs of 12 HIV-negative and 12 HIV+ART donors and differentiated into MDMs. The mRNA and protein expression of drug transporters and metabolic enzymes were analyzed by quantitative real-time polymerase chain reaction and flow cytometry, respectively. ARV drug concentrations were quantified in plasma, PBMCs, monocytes, and MDMs by LC-MS/MS. The mRNA expression of relevant ARV transporters or metabolic enzymes, ABCB1/P-gp, ABCG2/BCRP, ABCC1/MRP1, ABCC4/MRP4, SLC22A1/OCT1, SLC29A2/ENT2, CYP2B6, CYP2D6, and UGT1A1, was demonstrated in monocytes and MDMs of 2 to 4 HIV-negative donors. P-gp, BCRP, and MRP1 proteins were differentially expressed in classical, intermediate, and nonclassical monocytes and MDMs of both HIV+ART and HIV-negative donors. Intracellular concentrations of ARVs known to be substrates of these transporters and metabolic enzymes were detected in monocytes of HIV+ART donors but were undetectable in MDMs. In this study, we demonstrated the expression of drug transporters and metabolic enzymes in monocytes and MDMs of HIV-negative and HIV+ART individuals, which could potentially limit intracellular concentrations of ARVs and contribute to residual HIV replication. Further work is needed to assess the role of these transporters in the penetration of ARVs in tissue macrophages.
Copyright © 2021 Wolters Kluwer Health, Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2021        PMID: 34153016      PMCID: PMC8346207          DOI: 10.1097/QAI.0000000000002682

Source DB:  PubMed          Journal:  J Acquir Immune Defic Syndr        ISSN: 1525-4135            Impact factor:   3.771


  61 in total

1.  Changes in immunological and virological parameters in HIV-1 infected subjects following leukapheresis.

Authors:  M R Boulassel; G Spurll; D Rouleau; C Tremblay; M Edwardes; R P Sekaly; R Lalonde; J-P Routy
Journal:  J Clin Apher       Date:  2003       Impact factor: 2.821

Review 2.  HIV reservoirs and strategies for eradication.

Authors:  Miranda Z Smith; Fiona Wightman; Sharon R Lewin
Journal:  Curr HIV/AIDS Rep       Date:  2012-03       Impact factor: 5.071

3.  HIV-TAT protein upregulates expression of multidrug resistance protein 1 in the blood-brain barrier.

Authors:  Kentaro Hayashi; Hong Pu; Ibolya E Andras; Sung Yong Eum; Atsushi Yamauchi; Bernhard Hennig; Michal Toborek
Journal:  J Cereb Blood Flow Metab       Date:  2005-12-14       Impact factor: 6.200

4.  Modulation of the intracellular accumulation of saquinavir in peripheral blood mononuclear cells by inhibitors of MRP1, MRP2, P-gp and BCRP.

Authors:  Omar Janneh; Andrew Owen; Becky Chandler; Ruben C Hartkoorn; C Anthony Hart; Patrick G Bray; Stephen A Ward; David J Back; Saye H Khoo
Journal:  AIDS       Date:  2005-12-02       Impact factor: 4.177

5.  Cytochrome P450 1B1: a major P450 isoenzyme in human blood monocytes and macrophage subsets.

Authors:  J M Baron; G Zwadlo-Klarwasser; F Jugert; W Hamann; A Rübben; H Mukhtar; H F Merk
Journal:  Biochem Pharmacol       Date:  1998-11-01       Impact factor: 5.858

6.  Expression of breast cancer resistance protein in peripheral T cell subsets from HIV‑1‑infected patients with antiretroviral therapy.

Authors:  Jiu-Cong Zhang; Zhi-Yun Deng; Yong Wang; Fang Xie; Li Sun; Fang-Xin Zhang
Journal:  Mol Med Rep       Date:  2014-05-29       Impact factor: 2.952

7.  Validation of the CNS Penetration-Effectiveness rank for quantifying antiretroviral penetration into the central nervous system.

Authors:  Scott Letendre; Jennifer Marquie-Beck; Edmund Capparelli; Brookie Best; David Clifford; Ann C Collier; Benjamin B Gelman; Justin C McArthur; J Allen McCutchan; Susan Morgello; David Simpson; Igor Grant; Ronald J Ellis
Journal:  Arch Neurol       Date:  2008-01

8.  Plasma and Intracellular Concentrations in HIV-Infected Patients Requiring Hemodialysis Dosed With Tenofovir Disoproxil Fumarate and Emtricitabine.

Authors:  James E Slaven; Brian S Decker; Angela D M Kashuba; Mohamed G Atta; Christina M Wyatt; Samir K Gupta
Journal:  J Acquir Immune Defic Syndr       Date:  2016-09-01       Impact factor: 3.731

9.  Failure of dideoxynucleosides to inhibit human immunodeficiency virus replication in cultured human macrophages.

Authors:  D D Richman; R S Kornbluth; D A Carson
Journal:  J Exp Med       Date:  1987-10-01       Impact factor: 14.307

10.  Polarized macrophage subsets differentially express the drug efflux transporters MRP1 and BCRP, resulting in altered HIV production.

Authors:  Hui He; Merrion Buckley; Bernard Britton; Ying Mu; Kristin Warner; Santosh Kumar; Theodore J Cory
Journal:  Antivir Chem Chemother       Date:  2018 Jan-Dec
View more
  1 in total

Review 1.  Pharmacogenomics of drug transporters for antiretroviral long-acting pre-exposure prophylaxis for HIV.

Authors:  Nomusa M Zondo; Parveen Sobia; Aida Sivro; Sinaye Ngcapu; Veron Ramsuran; Derseree Archary
Journal:  Front Genet       Date:  2022-09-29       Impact factor: 4.772

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.